Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia

Priscilla Wander; Laurence C. Cheung; Sandra S. Pinhanҫos; Luke Jones; Mark Kerstjens; Susan T.C.J.M. Arentsen-Peters; Sajla Singh; Grace Alyssa Chua; Patricia Garrido Castro; Pauline Schneider; M. Emmy M. Dolman; Bianca Koopmans; Jan J. Molenaar; Rob Pieters; C. Michel Zwaan; Rishi S. Kotecha; Ronald W. Stam

doi:10.1038/s41375-020-0895-9

Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia

Priscilla Wander
, Laurence C. Cheung
, Sandra S. Pinhanҫos
, Luke Jones
, Mark Kerstjens
, Susan T.C.J.M. Arentsen-Peters
, Sajla Singh
, Grace Alyssa Chua
, Patricia Garrido Castro
, Pauline Schneider
, M. Emmy M. Dolman
, Bianca Koopmans
, Jan J. Molenaar
, Rob Pieters
, C. Michel Zwaan
, Rishi S. Kotecha
, Ronald W. Stam

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

6 Citaten (Scopus)

Originele taal-2	Engels
Pagina's (van-tot)	2898-2902
Aantal pagina's	5
Tijdschrift	Leukemia
Volume	34
Nummer van het tijdschrift	11
DOI's	https://doi.org/10.1038/s41375-020-0895-9
Status	Gepubliceerd - 1 nov. 2020

Toegang tot document

10.1038/s41375-020-0895-9

Citeer dit

Wander, P., Cheung, L. C., Pinhanҫos, S. S., Jones, L., Kerstjens, M., Arentsen-Peters, S. T. C. J. M., Singh, S., Chua, G. A., Castro, P. G., Schneider, P., Dolman, M. E. M., Koopmans, B., Molenaar, J. J., Pieters, R., Zwaan, C. M., Kotecha, R. S., & Stam, R. W. (2020). Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia. Leukemia, 34(11), 2898-2902. https://doi.org/10.1038/s41375-020-0895-9

@article{6afb07eae0c7449bb314fb5b90a3ff1d,

title = "Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia",

keywords = "Animals, Antimetabolites, Antineoplastic/pharmacology, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Deoxycytidine/analogs \& derivatives, Disease Management, Disease Models, Animal, Drug Evaluation, Preclinical, Gene Rearrangement, Genetic Predisposition to Disease, Humans, Infant, Myeloid-Lymphoid Leukemia Protein/genetics, Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy, Gemcitabine",

author = "Priscilla Wander and Cheung, \{Laurence C.\} and Pinhanҫos, \{Sandra S.\} and Luke Jones and Mark Kerstjens and Arentsen-Peters, \{Susan T.C.J.M.\} and Sajla Singh and Chua, \{Grace Alyssa\} and Castro, \{Patricia Garrido\} and Pauline Schneider and Dolman, \{M. Emmy M.\} and Bianca Koopmans and Molenaar, \{Jan J.\} and Rob Pieters and Zwaan, \{C. Michel\} and Kotecha, \{Rishi S.\} and Stam, \{Ronald W.\}",

note = "Funding Information: Acknowledgements RSK is supported by a Fellowship from the National Health and Medical Research Council of Australia (NHMRC APP1142627). RSK and LCC are supported by the Children{\textquoteright}s Leukaemia and Cancer Research Foundation (CLCRF, Australia).",

year = "2020",

month = nov,

day = "1",

doi = "10.1038/s41375-020-0895-9",

language = "English",

volume = "34",

pages = "2898--2902",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "11",

}

Wander, P, Cheung, LC, Pinhanҫos, SS, Jones, L, Kerstjens, M, Arentsen-Peters, STCJM, Singh, S, Chua, GA, Castro, PG, Schneider, P, Dolman, MEM, Koopmans, B, Molenaar, JJ , Pieters, R , Zwaan, CM, Kotecha, RS & Stam, RW 2020, 'Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia', Leukemia, vol. 34, nr. 11, blz. 2898-2902. https://doi.org/10.1038/s41375-020-0895-9

TY - JOUR

T1 - Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia

AU - Wander, Priscilla

AU - Cheung, Laurence C.

AU - Pinhanҫos, Sandra S.

AU - Jones, Luke

AU - Kerstjens, Mark

AU - Arentsen-Peters, Susan T.C.J.M.

AU - Singh, Sajla

AU - Chua, Grace Alyssa

AU - Castro, Patricia Garrido

AU - Schneider, Pauline

AU - Dolman, M. Emmy M.

AU - Koopmans, Bianca

AU - Molenaar, Jan J.

AU - Pieters, Rob

AU - Zwaan, C. Michel

AU - Kotecha, Rishi S.

AU - Stam, Ronald W.

N1 - Funding Information: Acknowledgements RSK is supported by a Fellowship from the National Health and Medical Research Council of Australia (NHMRC APP1142627). RSK and LCC are supported by the Children’s Leukaemia and Cancer Research Foundation (CLCRF, Australia).

PY - 2020/11/1

Y1 - 2020/11/1

KW - Animals

KW - Antimetabolites, Antineoplastic/pharmacology

KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects

KW - Deoxycytidine/analogs & derivatives

KW - Disease Management

KW - Disease Models, Animal

KW - Drug Evaluation, Preclinical

KW - Gene Rearrangement

KW - Genetic Predisposition to Disease

KW - Humans

KW - Infant

KW - Myeloid-Lymphoid Leukemia Protein/genetics

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy

KW - Gemcitabine

UR - https://www.scopus.com/pages/publications/85085769393

U2 - 10.1038/s41375-020-0895-9

DO - 10.1038/s41375-020-0895-9

M3 - Article

C2 - 32488115

AN - SCOPUS:85085769393

SN - 0887-6924

VL - 34

SP - 2898

EP - 2902

JO - Leukemia

JF - Leukemia

IS - 11

ER -